197 related articles for article (PubMed ID: 20235836)
1. Long-term impact of acyclovir suppressive therapy on genital and plasma HIV RNA in Tanzanian women: a randomized controlled trial.
Tanton C; Weiss HA; Rusizoka M; Legoff J; Changalucha J; Baisley K; Mugeye K; Everett D; Belec L; Clayton TC; Ross DA; Hayes RJ; Watson-Jones D
J Infect Dis; 2010 May; 201(9):1285-97. PubMed ID: 20235836
[TBL] [Abstract][Full Text] [Related]
2. Impact of aciclovir on genital and plasma HIV-1 RNA in HSV-2/HIV-1 co-infected women: a randomized placebo-controlled trial in South Africa.
Delany S; Mlaba N; Clayton T; Akpomiemie G; Capovilla A; Legoff J; Belec L; Stevens W; Rees H; Mayaud P
AIDS; 2009 Feb; 23(4):461-9. PubMed ID: 19155993
[TBL] [Abstract][Full Text] [Related]
3. Impact of acyclovir on genital and plasma HIV-1 RNA, genital herpes simplex virus type 2 DNA, and ulcer healing among HIV-1-infected African women with herpes ulcers: a randomized placebo-controlled trial.
Mayaud P; Legoff J; Weiss HA; Grésenguet G; Nzambi K; Bouhlal H; Frost E; Pépin J; Malkin JE; Hayes RJ; Mabey DC; Bélec L;
J Infect Dis; 2009 Jul; 200(2):216-26. PubMed ID: 19530940
[TBL] [Abstract][Full Text] [Related]
4. High-dose valacyclovir decreases plasma HIV-1 RNA more than standard-dose acyclovir in persons coinfected with HIV-1 and HSV-2: a randomized crossover trial.
Perti T; Saracino M; Baeten JM; Johnston C; Diem K; Ocbamichael N; Huang ML; Selke S; Magaret A; Corey L; Wald A
J Acquir Immune Defic Syndr; 2013 Jun; 63(2):201-8. PubMed ID: 23542637
[TBL] [Abstract][Full Text] [Related]
5. Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2.
Celum C; Wald A; Lingappa JR; Magaret AS; Wang RS; Mugo N; Mujugira A; Baeten JM; Mullins JI; Hughes JP; Bukusi EA; Cohen CR; Katabira E; Ronald A; Kiarie J; Farquhar C; Stewart GJ; Makhema J; Essex M; Were E; Fife KH; de Bruyn G; Gray GE; McIntyre JA; Manongi R; Kapiga S; Coetzee D; Allen S; Inambao M; Kayitenkore K; Karita E; Kanweka W; Delany S; Rees H; Vwalika B; Stevens W; Campbell MS; Thomas KK; Coombs RW; Morrow R; Whittington WL; McElrath MJ; Barnes L; Ridzon R; Corey L;
N Engl J Med; 2010 Feb; 362(5):427-39. PubMed ID: 20089951
[TBL] [Abstract][Full Text] [Related]
6. A randomised placebo-controlled trial to explore the effect of suppressive therapy with acyclovir on genital shedding of HIV-1 and herpes simplex virus type 2 among Zimbabwean sex workers.
Cowan FM; Pascoe SJ; Barlow KL; Langhaug LF; Jaffar S; Hargrove JW; Robinson NJ; Bassett MT; Wilson D; Brown DW; Hayes RJ
Sex Transm Infect; 2008 Dec; 84(7):548-53. PubMed ID: 18684855
[TBL] [Abstract][Full Text] [Related]
7. Reduction of HIV-1 RNA levels with therapy to suppress herpes simplex virus.
Nagot N; Ouédraogo A; Foulongne V; Konaté I; Weiss HA; Vergne L; Defer MC; Djagbaré D; Sanon A; Andonaba JB; Becquart P; Segondy M; Vallo R; Sawadogo A; Van de Perre P; Mayaud P;
N Engl J Med; 2007 Feb; 356(8):790-9. PubMed ID: 17314338
[TBL] [Abstract][Full Text] [Related]
8. Cervicovaginal HIV-1 and herpes simplex virus type 2 shedding during genital ulcer disease episodes.
LeGoff J; Weiss HA; Gresenguet G; Nzambi K; Frost E; Hayes RJ; Mabey DC; Malkin JE; Mayaud P; Belec L
AIDS; 2007 Jul; 21(12):1569-78. PubMed ID: 17630552
[TBL] [Abstract][Full Text] [Related]
9. Self-collected genital swabs compared with cervicovaginal lavage for measuring HIV-1 and HSV-2 and the effect of acyclovir on viral shedding.
McNicholl JM; Leelawiwat W; Whitehead S; Hanson DL; Evans-Strickfaden T; Cheng CY; Chonwattana W; Mueanpai F; Kittinunvorakoon C; Markowitz L; Dunne EF
Int J STD AIDS; 2017 Mar; 28(4):372-379. PubMed ID: 27179350
[TBL] [Abstract][Full Text] [Related]
10. Effect of herpes simplex suppression on incidence of HIV among women in Tanzania.
Watson-Jones D; Weiss HA; Rusizoka M; Changalucha J; Baisley K; Mugeye K; Tanton C; Ross D; Everett D; Clayton T; Balira R; Knight L; Hambleton I; Le Goff J; Belec L; Hayes R; ;
N Engl J Med; 2008 Apr; 358(15):1560-71. PubMed ID: 18337596
[TBL] [Abstract][Full Text] [Related]
11. Impact of suppressive herpes therapy on genital HIV-1 RNA among women taking antiretroviral therapy: a randomized controlled trial.
Ouedraogo A; Nagot N; Vergne L; Konate I; Weiss HA; Defer MC; Foulongne V; Sanon A; Andonaba JB; Segondy M; Mayaud P; Van de Perre P
AIDS; 2006 Nov; 20(18):2305-13. PubMed ID: 17117016
[TBL] [Abstract][Full Text] [Related]
12. Effect of HSV-2 suppressive therapy on genital tract HIV-1 RNA shedding among women on HAART: a pilot randomized controlled trial.
Nijhawan AE; Delong AK; Chapman S; Rana A; Kurpewski J; Ingersoll J; Caliendo AM; Cu-Uvin S
Infect Dis Obstet Gynecol; 2012; 2012():868526. PubMed ID: 22505800
[TBL] [Abstract][Full Text] [Related]
13. Patterns of herpes simplex virus shedding over 1 month and the impact of acyclovir and HIV in HSV-2-seropositive women in Tanzania.
Tanton C; Weiss HA; LeGoff J; Changalucha J; Clayton TC; Ross DA; Belec L; Hayes RJ; Watson-Jones D
Sex Transm Infect; 2011 Aug; 87(5):406-11. PubMed ID: 21653932
[TBL] [Abstract][Full Text] [Related]
14. Correlates of HIV-1 genital shedding in Tanzanian women.
Tanton C; Weiss HA; Le Goff J; Changalucha J; Rusizoka M; Baisley K; Everett D; Ross DA; Belec L; Hayes RJ; Watson-Jones D
PLoS One; 2011 Mar; 6(3):e17480. PubMed ID: 21390251
[TBL] [Abstract][Full Text] [Related]
15. High-dose valacyclovir HSV-2 suppression results in greater reduction in plasma HIV-1 levels compared with standard dose acyclovir among HIV-1/HSV-2 coinfected persons: a randomized, crossover trial.
Mugwanya K; Baeten JM; Mugo NR; Irungu E; Ngure K; Celum C
J Infect Dis; 2011 Dec; 204(12):1912-7. PubMed ID: 21998479
[TBL] [Abstract][Full Text] [Related]
16. Daily acyclovir to decrease herpes simplex virus type 2 (HSV-2) transmission from HSV-2/HIV-1 coinfected persons: a randomized controlled trial.
Mujugira A; Magaret AS; Celum C; Baeten JM; Lingappa JR; Morrow RA; Fife KH; Delany-Moretlwe S; de Bruyn G; Bukusi EA; Karita E; Kapiga S; Corey L; Wald A;
J Infect Dis; 2013 Nov; 208(9):1366-74. PubMed ID: 23901094
[TBL] [Abstract][Full Text] [Related]
17. Effect of aciclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: a randomised, double-blind, placebo-controlled trial.
Celum C; Wald A; Hughes J; Sanchez J; Reid S; Delany-Moretlwe S; Cowan F; Casapia M; Ortiz A; Fuchs J; Buchbinder S; Koblin B; Zwerski S; Rose S; Wang J; Corey L;
Lancet; 2008 Jun; 371(9630):2109-19. PubMed ID: 18572080
[TBL] [Abstract][Full Text] [Related]
18. Suppressive acyclovir therapy reduces HIV cervicovaginal shedding in HIV- and HSV-2-infected women, Chiang Rai, Thailand.
Dunne EF; Whitehead S; Sternberg M; Thepamnuay S; Leelawiwat W; McNicholl JM; Sumanapun S; Tappero JW; Siriprapasiri T; Markowitz L
J Acquir Immune Defic Syndr; 2008 Sep; 49(1):77-83. PubMed ID: 18667923
[TBL] [Abstract][Full Text] [Related]
19. Effect of acyclovir on HIV-1 set point among herpes simplex virus type 2-seropositive persons during early HIV-1 infection.
Kim HN; Wang J; Hughes J; Coombs R; Sanchez J; Reid S; Delany-Moretlwe S; Cowan F; Fuchs J; Eshleman SH; Khaki L; McMahon MA; Siliciano RF; Wald A; Celum C
J Infect Dis; 2010 Sep; 202(5):734-8. PubMed ID: 20649426
[TBL] [Abstract][Full Text] [Related]
20. Impact of aciclovir on ulcer healing, lesional, genital and plasma HIV-1 RNA among patients with genital ulcer disease in Malawi.
Phiri S; Hoffman IF; Weiss HA; Martinson F; Nyirenda N; Kamwendo D; Fiscus SA; Chen CY; Miller WC; van der Hoeven L; Chilongozi D; Cohen MS; Mayaud P
Sex Transm Infect; 2010 Oct; 86(5):345-52. PubMed ID: 20444742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
